ClinicalTrials.gg
CompletedNCT03694353Updated Feb 17, 2022Results posted

Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU

A Phase 3 interventional study of Pegvaliase in Phenylketonuria (PKU), sponsored by BioMarin Pharmaceutical. Completed at 17 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-02-17.

Sponsored by BioMarin Pharmaceutical · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing pegvaliase in Phenylketonurias — 1 open to participants now, 2 under way, 1 of them phase 3. pegvaliase · Phenylketonurias.

Enrollment
6th of 10
37 · median 39
Started
2018
the only one that year
Phase 3
4 of 10
none open now
Registered
8th of 10
by date
Lead sponsor
10 of 10
BioMarin Pharmaceutical

Among the 10 studies testing pegvaliase in Phenylketonurias, this one is the 6th largest by enrollment, is the only one that started in 2018, is one of 4 in phase 3, and was the 8th registered.

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

Browse Phenylketonurias studies →

Open to participants now

1 of the 10 studies testing pegvaliase in Phenylketonurias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegvaliase

pegvaliase: first FDA approval 2018 (PALYNZIQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing pegvaliase in Phenylketonurias, or all of them as a file.
02

Study summary

This is a Phase 3 open-label extension study enrolling adult patients with PKU who were previously treated with pegvaliase in Studies PAL-003 (NCT00924703) or 165-302 (NCT02468570). The study is designed to evaluate the long-term safety and efficacy of pegvaliase administered at doses > 40 mg/day to 60 mg/day.

Read the detailed description

Pegvaliase dosing will continue without interruption from Parent Study 165-302 (NCT02468570) or Parent Study PAL-003 (NCT00924703). Beginning on Day 1, subjects will receive the same dose and regimen of pegvaliase they were receiving in either 165-302 or PAL-003. A subject who reduces to a dose of 40 mg/day or lower for 32 consecutive weeks will be discontinued from study drug and withdrawn from the study as they will have the option to transition to commercial drug. Dose reductions may be performed if warranted due to AEs or hypophenylalaninemia. Dose increases to up to 60 mg/day may be performed per investigator discretion in consultation with the sponsor's medical monitor. Dosing will continue for approximately 121 weeks.

03

Conditions studied

  • Phenylketonuria (PKU)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be enrolled in PAL-003 or 165-302 Part 4 at the time of screening for 165-304 and most recently receiving pegvaliase at a dose > 40 mg/day.
  • Has identified a competent person or persons ≥ 18 years of age who can observe the subject during study drug administration and for a minimum of 1 hour following administration in situations required per protocol.
  • For females with , must have negative pregnancy test at screening and be willing to have additional pregnancy tests during the study.
  • If sexually active and not planning to become pregnant (self or partner), must be willing to use 2 acceptable methods of while participating in the study and for 4 weeks after the study.
  • Is willing and able to provide written, signed after the nature of the study has been explained and prior to any research-related procedures; a legally authorized representative may provide written consent and assent may be requested.
  • Is willing and able to comply with all study procedures.
  • Is in generally good health, as evidenced by physical examination and/or clinical laboratory evaluations (hematology, chemistry, and urinalysis).

Exclusion criteria

Exclusion criteria:

  • Use of any product (except pegvaliase) or investigational medical device within 30 days prior to screening or requirement for any investigational agent prior to completion of all scheduled study assessments.
  • Use of any medication (except pegvaliase) intended to treat PKU, including the use of large neutral amino acids, within 2 days prior to the administration of pegvaliase (Day 1).
  • Use or planned use of any injectable drugs containing PEG (other than pegvaliase), including medroxyprogesterone injection, within 3 months prior to screening and during study participation.
  • A history of organ transplantation or on chronic therapy
  • A history of substance abuse (as defined by the American Psychiatric Association: [DSM]) in the past 12 months or current alcohol or drug abuse
  • Current participation in the Kuvan® registry study (PKU Demographics, Outcomes and Safety [PKUDOS])
  • Concurrent disease or condition that would interfere with study participation or safety (eg, history or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, oncologic, or psychiatric disease)
  • Any condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or terminating early from the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Pegvaliase

    Beginning on Day 1, subjects will receive the same dose and regimen of pegvaliase they were receiving in 165-302 or PAL-003 (pegvaliase dosing should continue without interruption from the previous study). Subsequent revisions to dosing regimens are allowed following consultation with the medical monitor.

    Drug: Pegvaliase

Interventions

  • 40-60mg/day

    Also known as: rAvPAL-PEG

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0

    A treatment-emergent AE was defined as any adverse event (AE) newly appearing or worsened in severity following initiation of study drug until 4 weeks after last dose of pegvaliase

    Time frame: Up to Day 741 (approximately Week 106)

  2. Change in Blood Phe Concentration

    Change in blood phenylalanine (Phe) concentration from Parent Study baseline (naïve/pretreatment).

    Time frame: The Outcome Measure Data Table below uses the 'analysis visit' as defined by the mapping rule in the SAP. The last Phe measurement was mapped to 'analysis visit' week 121. The actual date of the last Phe measurement was day 836 (approximately Week 119).

07

Results

Posted Feb 17, 2022

Participant flow

This was a multicenter study, conducted in 17 study centers in the United States involving subjects from either Parent Study 165-302 (NCT02468570) or Parent Study PAL-003 (NCT00924703).

Participant flow — Overall Study
MilestoneAll Subjects
Started37
Completed35
Not completed2
Withdrew: Withdrawal by subject1
Withdrew: Subject received <= 40 mg/day for > 32 weeks1

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0

A treatment-emergent AE was defined as any adverse event (AE) newly appearing or worsened in severity following initiation of study drug until 4 weeks after last dose of pegvaliase

Time frame:
Up to Day 741 (approximately Week 106)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0
ParticipantsAll Subjects
TEAE36
Related TEAE17
Serious TEAE7
Related Serious TEAE1
PrimaryChange in Blood Phe Concentration

Change in blood phenylalanine (Phe) concentration from Parent Study baseline (naïve/pretreatment).

Time frame:
The Outcome Measure Data Table below uses the 'analysis visit' as defined by the mapping rule in the SAP. The last Phe measurement was mapped to 'analysis visit' week 121. The actual date of the last Phe measurement was day 836 (approximately Week 119).
Reported as:
Mean · µmol/L
Change in Blood Phe Concentration
µmol/LAll Subjects
Parent Study Baseline (naïve/pretreatment)1376.9 ± 289.77
Change from Baseline to Screening/Day 1-761 ± 506.7
Change from Baseline at week 9-970.6 ± 513.6
Change from Baseline at Week 17-963.4 ± 454
Change from Baseline at Week 25-830.6 ± 599.8
Change from Baseline at Week 33-999.8 ± 528
Change from Baseline at Week 41-984.1 ± 545.6
Change from Baseline at Week 49-1001.7 ± 518.3
Change from Baseline at Week 57-867 ± 569.2
Change from Baseline at Week 65-913.2 ± 445
Change from Baseline at Week 73-896 ± 582.8
Change from Baseline at Week 81-847.8 ± 504
Change from Baseline at Week 89-962.3 ± 482.6
Change from Baseline at Week 97-865.6 ± 567.4
Change from Baseline at Week 105-817.4 ± 584.9
Change from Baseline at Week 113-1319 ± 123
Change from Baseline at Week 121-1123 ± NA

Adverse events

Collected over Up to Day 741 (approximately Week 106). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Subjects0/37 (0%)7/37 (18.9%)36/37 (97.3%)
Most frequent serious events
Most frequent serious events
EventAll Subjects
COVID-19Infections and infestations1/37
Wound infection staphylococcalInfections and infestations1/37
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/37
Ectopic pregnancyPregnancy, puerperium and perinatal conditions1/37
Gastric ulcer haemorrhageGastrointestinal disorders1/37
Systemic inflammatory response syndromeGeneral disorders1/37
CholecystitisHepatobiliary disorders1/37
Anaphylactic reactionImmune system disorders1/37
Most frequent other events
Showing 10 of 64
Most frequent other events
EventAll Subjects
NasopharyngitisInfections and infestations13/37
HeadacheNervous system disorders12/37
InfluenzaInfections and infestations7/37
Oropharyngeal painRespiratory, thoracic and mediastinal disorders7/37
Amino acid level decreasedInvestigations7/37
NauseaGastrointestinal disorders6/37
VomitingGastrointestinal disorders6/37
Injection site bruisingGeneral disorders6/37
ArthralgiaMusculoskeletal and connective tissue disorders6/37
PruritusSkin and subcutaneous tissue disorders6/37

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Subjects
Mean28.84 ± 9.02
Age, Customized
Age, Customized(Participants)All Subjects
16 to < 18 years2
Between 18 and < 66 years35
>/= 66 years0
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects
Female15
Male22
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Subjects
Hispanic or Latino1
Not Hispanic or Latino36
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Subjects
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White36
More than one race1
Unknown or Not Reported0
Weight
Weight(kg)All Subjects
Mean94.9 ± 29.75
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)All Subjects
Mean32 ± 8.41
Baseline Blood Phe
Baseline Blood Phe(umol/L)All Subjects
Mean1376.9 ± 289.77
08

Study locations

17 sites
  • University of Florida
    Gainesville, Florida 32610, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Indiana CTSI Clinical Research Center
    Indianapolis, Indiana 46202, United States
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536, United States
  • Wayne State University, Center for Molecular Medicine and Genetics, Pediatrics and Pathology
    Detroit, Michigan 48201, United States
  • University of Missouri Health Care
    Columbia, Missouri 65201, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Morristown Medical Center
    Morristown, New Jersey 07960, United States
  • University of Oklahoma Health Science Center
    Oklahoma City, Oklahoma 73104, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • St. Christopher's Hospital for Children
    Philadelphia, Pennsylvania 19134, United States
  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Medical College of Milwaukee
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Jan 2021, 28 months.

Results were first posted in Feb 2022, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2018
First posted
Oct 3, 2018
StartActual
Sep 13, 2018
Primary completionActual
Jan 13, 2021
CompletionActual
Jan 13, 2021
Results first posted
Feb 17, 2022
Last update
Feb 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03694353
Responsible party
Sponsor
First posted
Oct 3, 2018
Start date
Sep 13, 2018
Primary completion
Jan 13, 2021
Completion
Jan 13, 2021
Results posted
Feb 17, 2022
Last update
Feb 17, 2022

Study contacts

Medical Director, MD
study director · BioMarin Pharmaceutical

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegvaliase

Start the discussion